Serious Skin Reaction Associated with Imatinib in a Patient with Chronic Myeloid Leukemia
Imatinib mesylate (STI 571) is one of the fundamental chemotherapeutic agents used in the treatment of the chronic, accelerated and blastic phases of chronic myelocytic leukemia (CML), gastrointestinal stromal tumors and Philadelphia chromosome–positive ...
Murat Albayrak +6 more
doaj +1 more source
Avaliação de parâmetros laboratoriais e clínicos de pacientes portadores de leucemia mielóide crônica submetidos ao tratamento com mesilato de imatinibe e sua relação com alterações observadas no estroma da medula óssea Correlation between laboratory and clinical parameters of chronic myeloid leukemia patients treated with imatinib mesylate and its relationship with stromal changes observed in bone marrow biopsy [PDF]
Dissertação (mestrado) - Universidade Federal de Santa Catarina, Centro de Ciências da Saúde. Programa de Pós-graduação em FarmáciaA leucemia mieloide cronica (LMC) e uma doenca mieloproliferativa clonal, responsavel por 14% de todos os casos de ...
Caroline R. de Jesus +1 more
core +1 more source
A unique case of a 50-year-old Japanese male with jejunal leiomyosarcoma (LMS) who subsequently developed gastrointestinal stromal tumor (GIST) and desmoid tumor (DT) during five years and six months after the initial surgery is reported. The patient was
Yuji Kurihara +2 more
doaj +2 more sources
Acute and Chronic Leukemia in Sub‐Saharan Africa: A Systematic Review
ABSTRACT Background The four primary subgroups of leukemia include chronic myeloid leukemia (CML), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and chronic lymphocytic leukemia (CLL). Very little is known about the regional variation of leukemia and subtypes in sub‐Saharan Africa (SSA).
Allwell A. Ayirebi +17 more
wiley +1 more source
Background Incubation of chronic myeloid leukemia cells in hypoxia inhibits growth and selects BCR/Abl-independent cells with stem cell properties which are refractory to imatinib-mesylate.
Serena Giuntoli +5 more
doaj +1 more source
Abstract In pharmaceutical industries, continuous manufacturing methods have already been well established to improve productivity and process intensification. However, to better understand the trade‐offs of continuous crystallizers over the existing batch production systems, a robust technoeconomic cost and sustainability analysis is necessary to ...
Jungsoo Rhim, Zoltan K. Nagy
wiley +1 more source
ABSTRACT Dermatofibrosarcoma protuberans is a rare dermal and subcutaneous soft‐tissue tumor, uncommon in children, characterized by CD34 positivity and COL1A1‐PDGFB fusion. Prognosis is generally good, but local recurrence risk is high, so complete excision with clear margins and six‐monthly follow‐up for three years after surgery is recommended in ...
Sima Shamshiri Khamene +3 more
wiley +1 more source
Surface engineering converts pollen‐derived sporopollenin capsules into functional tools for medicine. Chemical, biological, and physical modifications give these natural carriers new properties. The modified capsules can release drugs on demand, recognize diseased tissues, and assist in diagnosis.
Qian Liu +9 more
wiley +1 more source
Uptake of synthetic low density lipoprotein by leukemic stem cells — a potential stem cell targeted drug delivery strategy [PDF]
Chronic Myeloid Leukemia (CML) stem/progenitor cells, which over-express Bcr-Abl, respond to imatinib by a reversible block in proliferation without significant apoptosis.
Jørgensen, Heather G. +25 more
core +1 more source
Systematic Review of Escalated Imatinib Doses Compared with Sunitinib or Best Supportive Care, for the Treatment of People with Unresectable/Metastatic Gastrointestinal Stromal Tumours Whose Disease has Progressed on the Standard Imatinib Dose [PDF]
PMID: 21971958 [PubMed - indexed for MEDLINE] PMCID: PMC3348468 Free PMC Article This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in ...
Pawana Sharma +15 more
core +1 more source

